Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607901-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $139.90 | |
A607901-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $359.90 | |
A607901-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $563.90 | |
A607901-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $933.90 |
Synonyms | compound 16 [PMID: 34423975] | azenosertib | Azenosertib [INN] | EX-A6113 | 9J13XU96Z1 | (R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one | |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of WEE1 G2 checkpoint kinase |
Product Description | ZN-c3 is a potent and selective Wee1 inhibitor with balanced potency, ADME, and pharmacokinetic properties. |
ALogP | 3.7 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one |
---|---|
INCHI | InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m1/s1 |
InChi Key | OXTSYWDBUVRXFF-GDLZYMKVSA-N |
Canonical SMILES | O=c1n(CC=C)n(c2ccc3CC[C@@](CC)(O)c3n2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc12 |
Isomeric SMILES | CC[C@]1(CCC2=C1N=C(C=C2)N3C4=NC(=NC=C4C(=O)N3CC=C)NC5=CC=C(C=C5)N6CCN(CC6)C)O |
PubChem CID | 139467635 |
Molecular Weight | 526.63 |
PubChem CID | 139467635 |
---|---|
RCSB PDB Ligand | 05J |
CAS Registry No. | 2376146-48-2 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C2414166 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414167 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414168 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414169 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414170 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414171 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414172 | Certificate of Analysis | Jan 29, 2024 | A607901 |
C2414173 | Certificate of Analysis | Jan 29, 2024 | A607901 |
Solubility | DMSO: 10mg/mL (18.99mM), Need ultrasonic. |
---|
1. Huang PQ, Boren BC, Hegde SG, Liu H, Unni AK, Abraham S, Hopkins CD, Paliwal S, Samatar AA, Li J et al.. (2021) Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.. J Med Chem, 64 (17): (13004-13024). [PMID:34423975] |